3SBio Inc (83B) - Cash Flow Conversion Efficiency
Based on the latest financial reports, 3SBio Inc (83B) has a cash flow conversion efficiency ratio of 0.037x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€592.24 Million ≈ $692.39 Million USD) by net assets (€15.96 Billion ≈ $18.66 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can 3SBio Inc fund operations to measure how many days the company can operate on defensive assets alone.
3SBio Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how 3SBio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
3SBio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 3SBio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
United Plantations Bhd
KLSE:2089
|
0.304x |
|
Zalando SE
XETRA:ZAL
|
-0.162x |
|
Bank of Ayudhya Public Company Limited
F:NVAU
|
0.070x |
|
Westports Holdings Bhd
KLSE:5246
|
0.083x |
|
Turkcell Iletisim Hizmetleri A.S
F:TUL1
|
0.103x |
|
Jiangsu Jiejie Microelectronics Co Ltd
SHE:300623
|
0.025x |
|
CCC Intelligent Solutions Holdings Inc. Common Stock
NASDAQ:CCCS
|
0.021x |
|
China Great Wall Securities Co Ltd Class A
SHE:002939
|
0.132x |
Annual Cash Flow Conversion Efficiency for 3SBio Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of 3SBio Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 83B company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €30.44 Billion ≈ $35.58 Billion |
€9.67 Billion ≈ $11.30 Billion |
0.318x | +78.98% |
| 2024-12-31 | €18.04 Billion ≈ $21.09 Billion |
€3.20 Billion ≈ $3.74 Billion |
0.177x | +40.72% |
| 2023-12-31 | €16.51 Billion ≈ $19.31 Billion |
€2.08 Billion ≈ $2.44 Billion |
0.126x | -10.91% |
| 2022-12-31 | €15.40 Billion ≈ $18.00 Billion |
€2.18 Billion ≈ $2.55 Billion |
0.142x | +31.48% |
| 2021-12-31 | €14.66 Billion ≈ $17.14 Billion |
€1.58 Billion ≈ $1.85 Billion |
0.108x | +4.86% |
| 2020-12-31 | €13.09 Billion ≈ $15.31 Billion |
€1.34 Billion ≈ $1.57 Billion |
0.103x | -43.64% |
| 2019-12-31 | €10.36 Billion ≈ $12.11 Billion |
€1.89 Billion ≈ $2.21 Billion |
0.182x | +41.09% |
| 2018-12-31 | €8.91 Billion ≈ $10.41 Billion |
€1.15 Billion ≈ $1.34 Billion |
0.129x | -8.27% |
| 2017-12-31 | €7.63 Billion ≈ $8.92 Billion |
€1.07 Billion ≈ $1.26 Billion |
0.141x | -5.15% |
| 2016-12-31 | €6.77 Billion ≈ $7.91 Billion |
€1.00 Billion ≈ $1.17 Billion |
0.148x | -- |
About 3SBio Inc
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thromboc… Read more